608 Q2W

DRUG2 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Plaque Psoriasis PatientsPsoriasis

Phase 3

A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

CompletedNCT05536726

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Psoriasis

Start: 2023-01-07End: 2024-06-04Updated: 2025-03-11

An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

Not yet recruitingNCT06299982

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Plaque Psoriasis Patients

Start: 2024-05-15End: 2025-03-20Target: 750Updated: 2024-03-08

Related Papers

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study

Frontiers in Immunology2026-06-09